CoDev Products Clause Samples
CoDev Products. With respect to each CoDev Product, to the extent not already provided, a Party shall make available to the other Party as soon as practicable all material Know-How (or, at the request of the other Party, any other Know-How) Controlled by such Party at the time of the PIRS CoDev Option Exercise Effective Date and that comes into existence from time to time thereafter that is relevant to the continued Development, Manufacturing or Commercialization of the CoDev Product, including Know-How generated pursuant to the applicable CoDev Product Plan or under any Unsponsored Work in accordance with Section 4.4.3.
CoDev Products. On CoDev Product-by-CoDev Product basis, if Pieris has exercised the applicable CoDev Option or if Pieris has an unexpired CoDev Option with respect to such Product, the Parties shall discuss in good faith and mutually agree on the supply of such Product for the conduct of any Clinical Study prior to commercial scale Manufacturing, and Manufacturing and supply activities shall be set forth in the applicable Collaboration Product Development Plan.
CoDev Products. 4.4.3.1. Following selection of the Target for a CoDev Product and the preparation of the initial Collaboration Product Development Plan for such Product under Section 4.3.3.1, Pieris will [***] until [***] stage is achieved.
4.4.3.2. After [***] stage is achieved, AstraZeneca will assume responsibility for all costs for the Research, Development, Manufacture, and Commercialization of the CoDev Product, unless and until such time as Pieris exercises the CoDev Product CoDev Option with respect to such Product.
4.4.3.3. Concurrent with execution of the CoDev Product CoDev Option, Pieris shall select whether it wishes to [***] split the Development Costs associated with the continued Development and Manufacture of the CoDev Product (“[***]”) or whether it wishes to contribute [***] percent ([***]%) of the Development Costs associated with the continued Development and Manufacture of the CoDev Product (the “[***] Split Option”). Should the total budget for the updated Collaboration Product Development Plan as set forth in Section 4.5.2.2 exceed [***] dollars ($[***]), then Pieris may, in the alternative, elect to contribute [***] percent ([***]%) of the Development Costs associated with the continued Development and Manufacture of such CoDev Product up to a cap of [***] dollars ($[***]) (the “[***] Cap Option”).
4.4.3.4. AstraZeneca shall at all times be responsible for all costs associated with Commercialization of the CoDev Product. In the event that Pieris exercises it Co-Commercialization Option under Section 7.1, AstraZeneca shall be responsible for [***] co-Commercializing the CoDev Product as set forth in Section 7.2.
4.4.3.5. If Pieris exercises its Opt-Out Option with respect to a CoDev Product under Section 4.6, then Pieris shall no longer be responsible for contributing to the Development Costs for such Product once the Opt-Out Option Notice is delivered to AstraZeneca.
CoDev Products. 4.4.3.1. Following selection of the Target for a CoDev Product and the preparation of the initial Collaboration Product Development Plan for such Product under Section 4.3.3.1, Pieris will [***] until [***] stage is achieved.
4.4.3.2. After [***] stage is achieved, AstraZeneca will assume responsibility for all costs for the Research, Development, Manufacture, and Commercialization of the CoDev Product, unless and until such time as Pieris exercises the CoDev Product CoDev Option with respect to such Product.